

# Index

## A

- AC powered asynchronous pacemaker, Zoll, 222, 223*f*
- Activating function, 164–165
  - contact length, effect on, 165
  - mathematical formalization, 165
  - of single and adjacent cathodes, normalized, 167*f*
- Activation of iridium oxide film (AIROF), 205
- Advanced Bionics Corporation (ABC), 86
- Advanced RISC machines (ARM), 57, 58
- Ag/AgCl,Cl<sup>-</sup> reference electrode, 225
  - biocompatibility, 225
- Age-related macular degeneration (AMD), 1–2, 5–6
- Alcock canal, 266
- Alfred Mann Foundation (AMF), 276
- Amputees, testing of concept, 281–282
  - longitudinal intrafascicular electrodes implanted in neuron clusters, 282*f*
- Analog to digital converter (ADC), 95
- Anesthesia, 72
- Application-specific integrated circuit (ASIC) chip, 94
  - backward pathway, 94
  - control units, 94–95
  - forward pathway, 94
- Argus<sup>TM</sup> II retinal prosthesis system, 11
- Argus<sup>TM</sup> 16 retinal implants, 9–10
- ARM, *see* Advanced RISC machines (ARM)
- Artificial implantable atrial pacemakers, 230–231
  - atrial leads (“J” shaped), 230, 231*f*
  - passive fixation, 230
  - atrioventricular (AV) block, control, 230
- Artificial implantable ventricular pacemakers, 224–230
  - bipolar pulse generator, 226*f*
  - lead testing, 230
  - programmability, 224–225
  - terminal assemblies, 226*f*
  - transvenous *vs.* transthoracic approach, 227
  - unipolar lead tip, 228*f*
- Artificial silicon retina (ASR) microchip, 12–13
- Artificial vision systems, 44
- ASIC chip, *see* Application-specific integrated circuit (ASIC) chip
- Asystole, 221, 243
- Atrial pacing, 230
  - dualchamber devices, 231
  - refractory ventricular tachycardia, control, 230
- Atropine eye solution, 72
- Auditory brainstem implant (ABI), 109, 118–120
  - array, 119*f*
  - hearing restoration in NF2 patients, aim, 119
- Auditory cortex implant (ACI), 109
- Auditory midbrain implant (AMI), 109
  - array
    - disadvantage of, 125
    - nonstimulated, tissue reaction, 133*f*
    - stimulated, tissue reaction, 134*f*
- Auditory nerve implant (ANI), 108
- Auditory prosthesis using DBS
  - design considerations, 122–127
  - device development and testing
    - feasibility and safety studies, 130–135
    - human prototype array, 127–130
  - electrode technologies, 147–149
  - implementation in humans, *see* Implementation in humans, auditory prosthesis using DBS
  - hearing performance, 144–146
  - patient fitting, 140–144
  - surgical approach, 135–140

- Auditory prosthesis using DBS (*cont.*)  
 rationale, 118–122  
 stimulation strategies, 149–150
- B**
- Bachmann's bundle, 231
- Back telemetry, 103–104  
 electrical stimulus artifact, reduction  
 methods, 103, 104<sup>f</sup>  
 functions of, 103  
 high and low electrode impedance,  
 effects, 103  
 NRT, 103
- Bakken pacemaker, 222, 224<sup>f</sup>
- Band-pass filters, 90
- Baropacers, 157
- Basham, Eric, 293–344
- Bed of nails (BON) electrode, 278
- Bicarbonate buffered saline (BBS), 23
- Bilateral cochlear implants, 108
- Binarization, 67–68
- Biocompatible materials  
 applications, 105, 105<sup>t</sup>  
 90%platinum–10% iridium  
 alloys, 105  
 safety, 104–105  
 selection, 105
- Biomaterials, 21
- Bion<sup>®</sup> microstimulator  
 and blunt dissector, 266<sup>f</sup>  
 clinical applications  
 BPB1, *see* BPB1 applications  
 RFB1, *see* RFB1 applications  
 RFB2, *see* RFB2 applications  
 design purpose and development, 255  
 development of, 254–255  
 BPB1, 260–261  
 BPB2, 261  
 RFB1, 255–256  
 RFB2, 256–260  
 occipital nerve, implantation adjacent  
 to, 269<sup>f</sup>  
 implantation adjacent to pudendal  
 nerve, 267<sup>f</sup>
- Biphasic pulse, 91
- Bipolar pulse generator, 226<sup>f</sup>
- Blindness, 1–3
- BOE, *see* Buffered oxide etching (BOE)
- Boltzmann's constant, 47
- Booth and Lidwell, 222
- BPB1, *see* First-generation battery-powered  
 bion microstimulator (BPB1)
- BPB1 applications  
 GERD, 270  
 overactive bladder, 266–268  
 UF treatment, 268  
 UUI treatment, 266–267  
 refractory headaches, 268–270
- BPB2, *see* Second-generation battery-powered  
 bion microstimulator (BPB2)
- Bradley, Kerry, 155–189
- Bradycardia, 221, 230, 235, 241, 243, 244  
 atrial pacing, use in, 230
- Brain, visual stimulation  
 cortical stimulation, 17–19  
 in LGN of thalamus, 19–20
- Brain control and sensing of artificial limbs  
 humans and animals, experiments  
 first human implant to control robotic  
 devices, 278–281  
 testing of concept in amputees, 281–282  
 Utah bed of nails electrode array,  
 development of, 276, 278
- limb loss and electrical neural stimulation  
 study in United States, 276  
 stimulation on peripheral nerves,  
 neurons, and neuroma, 277
- peripheral nerve interface  
 challenges and problems, *see*  
 Implantable miniature peripheral  
 nerve interface, challenges and  
 problems  
 implant design, 282–284
- Buffered oxide etching (BOE), 50–51
- Bumping, 287
- C**
- Capacitive electrodes, 30–31
- Capacitive mechanism, 30
- Carbunaru, Rafael, 253–271
- Cardiac Resynchronization Therapy (CRT)  
 devices, 232–235
- Cardiac rhythm timing pacemaker/ICD, 233<sup>f</sup>
- Cascode current mirrors, 96
- Cell body, 277
- Center for Devices and Radiological Health  
 (CDRH), 353
- Central controller, 254
- Central nucleus of inferior colliculus (ICC),  
 120, 122, 123, 126, 127, 131, 132,  
 133, 136, 138, 139, 140, 142, 145,  
 147, 148
- Ceramic sintering, 16
- Cerebellopontine angle, 136

- Chai, Xinyu, 43–81
- 7 channel stimulator, 16
- Charge-coupled device (CCD), 56
- Chinese characters, recognition of, 63–66
- Chip and crystal oscillator, 288
- Chip-scale package (CSP), *see* Thin-film, chip-size package
- Chronic pain, 157
- C6/7 implantation, 264
- Circular-Binarization, 67
- Circular-Edge images, 68
- Clarion™ array, 97
- Classification panels, regulatory approval in US, 354–357
- class I devices
    - general controls and standards, 354–355
  - class II devices, 355–356
    - clinical evaluation of, 356
    - noninvasive and higher risk devices, 355
    - premarket FDA approval, 355
  - class III devices, 356–357
    - pre-IDE meeting, 356–357
    - patients enrolled, statistical analysis, 356
- as per 21 CFR 862–892, 354
- See also* US regulatory approval process
- Clinical and physiological challenges, SCS, 161–162
- stimulation field, *see* Device programming in operating room and post-implant; Single- and multiple-source systems
- Clinical phase, implantable medical devices, 357–358
- pilot trial
    - purpose, 357
  - pivotal trial
    - endpoint of, 358
    - purpose, 357
- See also* US regulatory approval process
- Clinical trials, implantable medical devices
- IRB audits by FDA, 359
- See also* US regulatory approval process
- Closed-loop control of DBS, 209–210
- clinical trials for, 210
  - implementation of, challenges in, 209
  - neurotoxin MPTP injection in PD monkeys, 210
- Cochlear implants, 118*f*
- architecture and functional blocks, 88, 89*f*
  - development of, 86*f*
- DSP unit, 88
  - evaluation, 107
    - audiological criteria, 107
    - sentence recognition scores, 108*f*
  - external unit, 90–92
  - internal unit
    - back telemetry, 103–104
    - electrodes, 97–102
    - receiver and decoder, 94–96
    - stimulator, 96
  - microphone, design and functions, 88
  - radio frequency transmission link, 92–94
  - safety considerations
    - biocompatibility, 104–105
    - energy exposure, 106–107
    - mechanical safety, 106
    - sterilization, 105–106
  - spectral resolution of, 101
  - system, 87–89, 88*f*
- See also* Auditory prosthesis using DBS
- Code of Federal Regulations (CFR), 354
- Colvin, Mike, 353–370
- Combined acoustic and electric hearing, 108
- Communication unit, neural stimulator, 52–53
- Complementary metaloxide semiconductor (CMOS) cameras, 56–57
- Concordant paresthesia, 160, 161, 162, 175, 177, 178, 182
- Continuous interleaved sampling (CIS) strategy
  - vs.* n-of-m strategy, 90–91
- Contour™ electrode, 99–100
- Cortex, 6
- Cortical prostheses, 6
- Cortical stimulation, 17–19
- C-Sight (Chinese Project for Sight), 44
- Current electrodes, efficiency, and intracochlear trauma, 97–100
- intracochlear electrode arrays, 98*f*
  - reduction strategies used, 99–100
- Current Level (CL), 142
- Custom Sound, 141–142
- Cyberkinetics Neurotechnology Systems, Inc.
  - Michigan and Utah arrays, commercialization, 203
- Cylindrical form factor, 255
- D**
- DAC, *see* Digital analog converter (DAC)
- Dacron mesh, 127
- DBS, *see* Deep brain stimulation (DBS)

- Deep brain stimulation (DBS), 195
    - effects on depression, 198
    - efficacy of, 198
    - macroelectrode implantation, 196*f*
    - macroelectrodes and microelectrodes, characteristics of, 200*t*
    - microelectrode technologies in, 198–200
      - clinical use, strategies, 199–200
      - hybrid macro-and microelectrode array technology, 200
      - performance and biocompatibility, 199
    - pedunculopontine nucleus, target site treatment of PD, 198
    - ventral intermediate nucleus of thalamus, target of, 198
  - Deep reactive ion etching (DRIE), 203
  - Defense Advanced Research Program Agency (DARPA), 276
  - Design considerations, auditory prosthesis using DBS, 122–127
    - complexity and feasibility, 124
    - fabrication, 124
    - ICC stimulation, 123
    - limited bandwidth, 124
    - number of array sites, 124
    - small processor design, 124
  - Device programming in operating room and post-implant, 177–178
  - Digisonic MX20 device, 87
  - Digital analog converter (DAC), 54
  - Digital signal processor (DSP), 57, 58, 275
  - Digital to analog converter (DAC), 96
  - Dispersion and accuracy of simulated phosphene positioning, 68–72
  - Domestic applications, implantable medical devices
    - 180-day PMA supplements, 360
    - expedited PMAs, 360
    - original premarket approval (PMA), 360
    - panel-track supplements, 360
    - premarket notifications or 510(k)s, 359
    - premarket reports, 360
    - real-time PMA supplements, 360
  - Dopants, 204
  - Double-shank array, 147, 147*f*
    - advantage over single-shank array, 148
    - benefits, 148
  - DSP-based image processing system
    - hardware of, 57–58
    - strategies, 58–62
  - “Dual cathode” configuration, 232
  - Dual-chamber pacemakers (DDD), 222, 231–232
    - single chamber pacing, disadvantages over, 231–232
    - vs. VVI, 232
- E**
- Eddington, Donald, 87
  - Edge images, 65
  - Electric field optimization, 162–167
    - contact size and spacing, 163–167
      - activating function concept, 164
      - contact length on contact impedance, effect of, 163*f*
      - stimulation threshold, 164
    - implanted multiple contacts, 162
      - See also* Spinal cord stimulation (SCS)
  - Electric stimulation, 87–88
    - See also* Cochlear implants
  - Electrical management of lead migration, 173–176
    - location of leads, importance, 173
      - See also* Electric field optimization
  - Electrical pulse generator, 277
  - Electrical sources for stimulation, 167–173
    - excitation of axons, objective, 169
    - multiple-source systems, examples, 172–173, 172*f*
    - single-and multiple-source systems, 170–171, 171*f*
    - stimulation waveform, phases, 168–169, 168*f*
    - voltage and current regulation, 169–170
      - See also* Spinal cord stimulation
  - Electrical stimulation of biological tissue, 30
  - Electrical stimulators, *see* Neural electrical stimulator
  - Electrically evoked potentials (EEP), 15, 16, 74
    - damage to optic nerve, assessment of, 81
    - recordings, 75, 79
    - spatial responses to optic nerve stimulation, 79–80
    - stimulations, 74–75, 78–79
    - temporal properties of, 76–78
  - Electrode capacitance, 33
  - 22-electrode cochlear implant system, 86
  - Electrode fixation mechanisms
    - active, 227
    - passive, 227
  - Electrode impedance, 24–25
  - Electrodeposition iridium oxide film (EIROF), 205
    - advantage over AIROF and SIROF, 205

- Electrodes, internal unit, 97–103
    - cochlear implant electrode design, 101–102
    - current electrodes, efficiency, and intracochlear trauma, 97–100
    - insertion depth, 100–101
    - See also* Cochlear implants
  - Electrode driver unit, neural stimulator, 54–56
  - Electron micrographs of electrode surfaces, 240*f*
  - Embedded mode, RF frame coding, 92–94
  - Energy exposure
    - charge density, parameter, 106–107
    - implant environment and surface temperatures, design criteria, 107
    - safety considerations, cochlear implants, 106–107
  - Epiretinal implants, 8–12, 15
  - EtO sterilization process, 106
  - European device classification, *see* European regulatory approval process
    - class I, 368–369
    - class IIa, 369
    - class IIb, 369
    - class III, 369
  - European regulatory approval process. 367–368
    - European device classification, 368–369
  - European Union (EU) regulatory approval competent authority, responsibilities of, 367–368
    - notified bodies, 368
  - Expanded mode, RF frame coding, 92–93
  - External pacemakers, 222–223
    - temporary stimulation, use in hospitals, 222
  - External unit, cochlear implant, 90–92
    - CIS strategy, 90*f*
    - electrode arrays, properties of, 91*t*
    - “n-of-m” strategy, 91*f*
    - SPEAK strategy vs. ACE strategy, 90, 92
  - Extraocular implant, 15–17
  - Eyeball, 3, 74
- F**
- Fabrication technology and materials, 201
    - electrode materials, 204–206
    - iridium oxide, 205
    - potentiodynamic cycling, 205
    - proton electronation reaction, 205
    - polyimide, 201
    - substrates
      - batch processes, 201
      - ceramic (alumina)-based multisite array for DBS, Moxon, 203
      - metal-based arrays for DBS, Motta, 203
      - Michigan array vs. Utah array, doping action, 201–203
      - microwire-based technology vs. silicon-based technology, 203–204
      - photolithographic technologies, 200, 201
      - silicon, 200
      - silicon-on-insulator (SOI) arrays, 203
      - tissue damage/hemorrhages, reduction in risk, 201
      - Young’s modulus, 204
  - Failure modes and effects analysis (FMEA), 128–129
  - Faradaic mechanism, 30
  - Faradaic reactions, 205
  - Feasibility and safety studies, auditory prosthesis using DBS, 130–135
    - AMI histology, 135*f*
    - Giemsa-stained sections, 133
    - histomorphological effects, 133–135
    - stimulated and nonstimulated AMI array, 133
  - Feng, Haihong, 85–109
  - Fiber activity
    - opening and closing of gate, result of, 156–157
  - Fibrosis, 161
  - First-generation battery-powered bion microstimulator (BPB1), 260–261, 260*f*
    - design of, 260–261
    - internal layout of, 261*f*
    - Li-ion battery, use of, 260–261
  - First-generation RF-powered bion microstimulator (RFB1), 255–256, 255*f*
    - infrared laser welding, 255
    - tantalum oxide capacitor electrode, 255
  - FLASH, 57, 58
  - Floating multielectrode arrays (FMA), 49–50
  - Fluoroscopic imaging
    - disadvantages, 173
  - Focus of attention (FOA), 61
  - Foot drop
    - C6/7 implantation, 264
    - RFB1 application, treatment of, 264
  - Forel field, *see* Zona incerta

Freehand system, *see* FES  
 Functional electrical stimulation (FES), 253,  
 254, 294  
 Funke, H. D., 231

## G

Gastroesophageal reflux disease  
 (GERD), 270  
 Gate control system, 156*f*  
 theory of pain, 155, 156  
 Gating, 156  
 GERD, *see* Gastroesophageal reflux disease  
 (GERD)  
 BPBI applications, preclinical study, 270  
 endoscopic microstimulator  
 implantation, 270  
 Glaucoma, 3, 17  
 Globus pallidus (GPi), 197, 199, 201, 210, 211  
 Glucocorticosteroid, 239  
 Glucose, 3  
 Glutamate, 3  
 Gold electrode array on thin-film  
 polyimide, 26  
 Greenbaum, Elias, 1–36  
 Greenberg, Robert, J., 1–36  
 Grommets, 239

## H

Hachmair, Erwin, 87  
 Han, Martin, 195–212  
 Hard-case approach, 21  
 Harrison, William, V., 85–109  
 Head-mounted display (HMD), 64, 65  
 Hearing performance, auditory prosthesis  
 using DBS, 144–146  
 single-shank array, use, 144  
 Horchmair-Desoyer Ingeborg, 87  
 Human brain  
 with macroelectrode lead  
 implantation, 197*f*  
*See also* Brain, visual stimulation  
 Human eye, 4*f*  
 Humanitarian Device Exemptions (HDEs),  
 364–367  
 FDA submissions from 1997 to 2007,  
 365*t*–366*t*  
 Human prototype AMI array, 124–125,  
 127–130  
 CAD modeling of, 128*f*  
 components, 127  
 FEA method, 129, 129*f*

FMEA, risk analysis, 128  
 insertion into midbrain, 127  
 in vitro testing of, 129, 130*f*  
 Plan–Do–Check–Act (PDCA)  
 principle, 127  
 “check” phase of, 129  
 verification and validation tests, 130  
 Humayun group, 8–9  
 Hunter-Roth electrode, 225*f*  
 Hybrid circuit, components on, 287  
 Hybrid electric/acoustic (EAS) implant  
 systems  
 properties, 102*t*  
 Hybrid macro- and microelectrode array  
 technology  
 design and advantages, 200  
 Hyman, 222  
 external pacemaker, 223*f*

## I

ICC, *see* Central nucleus of inferior  
 colliculus (ICC)  
 ICD, *see* Implantable cardioverter  
 defibrillators (ICD)  
 ICD circuitry design elements, 238  
 Image acquisition, 56–57  
 Image classification, 59  
 complex image, 61–62  
 middle-complexity image, 60–61  
 simple image, 60  
 Image processing based recognition of  
 images with limited number of  
 pixels, 65–68  
 Image real-time processing, 57  
 Implant, internal construction of  
 bumping, 287  
 IC chip and components, cross section  
 of, 287*f*  
 reduction of wires and connections,  
 design criteria, 287  
 Implant packages  
 hard-case approach, 21  
 soft case approach, 21–22  
 thin-film chip-size package, 22  
 and biocompatibility, 21–24  
 Implant sites and applications, 197–198  
 Implantable cardiac electrostimulation  
 devices  
 clinical management of complications, and  
 related improvements over time  
 hardware complications, 247  
 medical complications, 246–247

- ICD implant, indications for, 245
- pacemaker, ICD, and lead codes, 222
- pacemaker implant, indications for
  - acquired AV Block, 243
  - atrial fibrillation (AF) and flutter, 244
  - cardiac conduction system, 242–243
  - cardiac transplantation, 244
  - heart failure, 244–245
  - hypersensitive carotid sinus and neurocardiogenic syncope, 244
  - sinus node dysfunction (Sick sinus syndrome or SSS), 243
  - tachyarrhythmias, prevention and termination, 243
- pacemakers and ICDs
  - artificial implantable atrial pacemakers, 230–231
  - artificial implantable ventricular pacemakers, 224–230
  - CRT devices, 232–235
  - dual-chamber pacemakers, 231–232
  - external pacemakers, 222–223
  - ICD circuitry design elements, 238
  - ICD power sources, 237
  - leads, 239–241
  - mechanical, 238–239
  - pacemaker circuitry design requirements, 237–238
  - pacemaker power sources, 236–237
  - programmability and automaticity, 241
- Implantable cardioverter defibrillators (ICD), 236, 236*f*
  - bipolar transvenous active fixation leads, 236
  - epicardial patch electrodes, 236
- Implantable medical devices
  - European regulatory approval process
    - European device classification, 368–369
    - European Union (EU) regulatory approval, 367–368
  - US regulatory approval process, 353–354
    - classification panels, 354–357
    - clinical phase, 357–358
    - clinical trials, 358–359
    - domestic applications, types of, 359–360
    - humanitarian device exemptions (HDEs), 364–367
- Implantable miniature peripheral nerve
  - interface, challenges and problems
  - chip and crystal oscillator, 288
  - clinicians fitting unit, 290
  - coil and antenna, 288
  - hybrid circuit, components on, 287
  - implant size, 286
  - indifferent electrodes, 288
  - internal construction of implant, 286–287
  - packaging hermeticity, 284–285
  - PMCU, 289–290
  - wireless communication, 288–289
  - wireless power, 288
- Implantable pulse generator (IPG), 158
  - stimulation sources, *see* Electrical sources for stimulation
- Implantable spinal cord stimulator, 159*f*
- Implementation in humans, auditory prosthesis using DBS, 144–146
  - surgical approach, 135–140
    - acoustic neuromas, removal, 135–136
    - AMI insertion at the tonotopic gradient of ICC, 136
    - array placement locations, 139*f* to IC, 137*f*
    - skin incision and suboccipital craniotomy, 137*f*
    - supracerebellar-infratentorial approaches, low risk, 136
- Ineraid device, 87
- Inferior colliculus (IC)
  - AMI, target site, 121
  - anatomy of, 122*f*
  - auditory pathway, 121*f*
- Insertion depth, electrodes, 100–101
  - “current steering”, 101, 102
  - frequency band and tonotopic location parameters, implant performance, 100
- Institutional Review Board (IRB), 355
- InSync model 7277, 233*f*
- Internal unit, cochlear implants, 94–104, 95*f*
  - back telemetry, 103–104
  - electrodes, 97–102
  - receiver and decoder, 94–96
  - stimulator, 96
- Intracochlear electrodes, 88
- Intracortical visual stimulation
  - system, 18–19
- Introducer, 200, 203, 204, 227, 229, 232
- Investigational device exemption (IDE), 355
- In vitro accelerated corrosion tests, 23
- Iridium oxide (IrO<sub>x</sub>), 32
  - activation by potentiodynamic cycling, 205
  - deposition methods, 205
  - desirable properties, 205

**J**

Jaax, Kristen, N., 253–271  
 Joint angle position, 275  
 Joint flexion sensors, 280  
*Journal of Neurophysiology*, 278

**K**

Keith needle, 224  
 Knee osteoarthritis  
   RFB1 application, treatment of, 263  
 Knee Society Pain-Free index, 263  
 510(k) review process, 355, 360–361, 362*f*  
   submission, 361  
   *See also* US regulatory approval process

**L**

Lateral canthotomy, 74  
 Lateral geniculate nucleus (LGN) of  
   thalamus, 19–20  
 Laura device, 87  
 Leads, 239–241  
   bipolar, 239  
   migration, 173  
   pacemaker and ICD, 239–241  
   passive fixation, 239  
   unipolar, 239  
   unipolar, bipolar and ICD assembly, 240*f*  
 Lee, Dongchul, C., 155–189  
 Lee model, 163  
 Lenarz, Minoo, 117–150  
 Lenarz, Thomas, 117–150  
 LeRoy (1755), 6  
 LGN of thalamus, *see* Lateral geniculate  
   nucleus (LGN) of thalamus  
 Li, Liming, 43–81  
 Lim, Hubert, H., 117–150  
 Limb Loss, study in US  
   amputee groups, age and gender, 276*t*  
   causes, 276  
 Li–silver vanadium oxide (SVO) batteries, 237  
 Li, Xiaoxin, 43–81  
 Liu, Wentai, 293–344  
 Lower esophageal sphincter (LES), 270  
 Low-pressure chemical vapor deposition  
   (LPCVD), 24

**M**

Macular degeneration, 6  
 McCreery, Douglas, B., 195–212  
 McVenes, Rick, 221–248

Mastoid process, 269  
 Mechanical safety, cochlear implants, 106  
   tissue trauma, prevention  
     stabilization and encapsulation, 106  
 Med El Combi 40 + <sup>TM</sup> intracochlear array, 98  
 Medtronic “Bisping” unipolar model  
   6957, 228*f*  
 Medtronic DBS “lead,” microscopic view, 197*f*  
 Medtronic models  
   2187 and 4193, 234*f*  
   6917 epi/myocardial lead, 227  
   6218, straight lead delivery sheaths, 235*f*  
 Medtronic ventricular pacemaker, 225*f*  
 Metal microwires, 46  
 “Michigan array”  
   boron-diffusion etch-stop process, 202  
   retractable introducers  
     aid for probe implantation, 203  
 Michigan array *vs.* Utah array, 201–203  
 Micro-camera, 44, 45, 56  
 Microelectrode arrays, 26–27, 29  
   based on various substrate platforms, 202*f*  
   components of, 200  
   penetration, 46  
   noise and impedance analyses, 46–48  
   silicon-based microelectrode, 50–52  
   tungsten shafts, 48–49  
   planar electrodes, 27–28  
   thin-film electrode, 28–30  
 Microelectrode technologies for deep brain  
   stimulation  
   closed-loop control of DBS, 209–210  
   design considerations and challenges,  
     198–200  
   key requirements, 198–200  
   fabrication technology and materials  
     electrode materials, 204–206  
     substrates, 200–204  
   implant sites and emerging applications,  
     197–198  
   recording capability and long-term  
     stability, 210–212  
   prolonged functionality of  
     microelectrodes, challenging  
     aspect, 211  
   stimulation parameters and requirements  
     of clinical system, 206–207  
   selection and calibration of, vital  
     factor, 206–207  
   spatial pattern of electrical  
     stimulation, control, 206  
   stimulation safety and tissue response,  
     207–209



Micro-electro-mechanical system (MEMS), 46, 50  
 Microelectronic visual prostheses, *see* Visual prostheses  
 Migraine Disability Assessment (MIDAS), 270  
 “Mix and match” of leads and generators, 225  
 Moffitt, Michael, A., 155–189  
 Motor neurons, 275, 277, 283, 288, 290  
 Myocardium, 224

## N

Nathan, D. A., 231  
 Needle-type electrode arrays, 27  
 Nerves in arm and leg, 277*f*  
 Neural electrical stimulator, 52  
   communication unit, 52–53  
   electrode driver unit, 54–56  
   processing and control unit, 53–54  
 Neural response telemetry (NRT), 103  
 Neurofibromatosis type 2 (NF2) patients, 119, 120, 135, 140, 145  
 Neuroma, 277  
 Neurostimulators, 157  
 Neurotrophic effect, 13  
 NF2, *see* Neurofibromatosis type 2 (NF2) patients  
 n-of-m strategy  
   *vs.* CIS strategy, 90–91  
 Non-invasive system, 276  
 Nonmultiwire cochlear implant, 254  
 Nonmultiwire spinal cord stimulator, 254  
 Norman, Dr. Richard, 278  
 NRT, *see* Neural response telemetry (NRT)  
 Nucleus device, 89  
 Nucleus freedom system, 94

## O

Occipital nerve, 268  
 Octopus type stimulator, *see* Bion<sup>®</sup> microstimulator  
 Office of Protection from Research Risks (OPRR), 358  
 Ohm’s law, 161, 169  
 One-to-one mapping, 94  
 Optic nerve stimulation, visual prosthesis, 20, 43–45, 45*f*  
   damage, assessment of, 81  
   DSP-based image processing system hardware of, 57–58  
   strategies, 58–62

image acquisition, 56–57  
*in vivo* electrophysiological study, 74  
   spatial properties, 78–80  
   subjects, 74  
   temporal properties, 74–78  
 microelectrode arrays, penetration, 46  
   noise and impedance analyses, 46–48  
   Pt/Ir alloy shafts, 49–50  
   silicon-based microelectrode arrays, 50–52  
   tungsten shafts, 48–49  
 neural electrical stimulator, 52  
   communication unit, 52–53  
   electrode driver unit, 54–56  
   processing and control unit, 53–54  
 psychophysical study, 62  
   Chinese characters with limited number of pixels, recognition of, 63–65  
   image processing based recognition of images with limited number of pixels, 65–68  
   simulated phosphene positioning, 68–72  
 surgical approach, 72  
   efficiency and safety, 73–74  
   technique, 72  
 Optoelectronic subretinal implants, 13  
 Oscilloscope, 277  
 Overactive bladder  
   BPB1 applications, 266–268  
   pudendal nerve stimulation, 266–268  
   remote control/charging system, 267  
 Oxidation–reduction reactions, *see* Faradaic reactions

## P

Pacemaker, ICD, and lead codes  
   electrode fixation mechanisms, 227  
     active, 227  
     passive, 227  
   letter codes, pacing terminology, 222  
 Pacemaker and ICD mechanical components, 238–239  
 Pacemaker circuitry design requirements, 237–238  
   basic design elements, 237–238  
 Pacemaker power sources  
   mercury–zinc vs. lithium iodide cells  
   nuclear batteries, benefits as, 237  
 Pacing system analyzer (PSA), 222

- Packaging hermeticity  
  iridium pin welded to titanium feed-through, 285*f*  
  titanium to ceramic feed-thru technology, 284, 285*f*  
  water absorbent, 284
- Paresthesia, 159–160  
  concordance, aid to pain relief, 160  
  engineering challenges, maintenance, 160  
  real-time tunability of, 173  
  *See also* Real-time programming strategies  
  serendipitous side effect, 160  
  use in SCS, 160
- Parinaud syndrome, 138
- Parkinson's disease (PD), 195
- Parylene C, 22
- Patient fitting, auditory prosthesis using DBS, 140–144  
  challenges, 142  
  demographic and implant-related information, NF2 patients, 140*t*
- Pedunculopontine nucleus, 198
- Penetrating electrode array, 74
- Penetrating microelectrode, 44
- Peripheral nerve interface  
  electrode connected to package components, protection of, 283  
  SBON in wireless system, concept, 284  
  two-way communication, 284
- Peripheral nerves, neurons, and neuroma, stimulation on  
  cell body, 277  
  motor neurons, 277  
  nerves in arm and leg, 277*f*  
  neuroma, formation of, 277  
  sensory neurons, 277
- Peripheral neurons, *see* Motor neurons
- Phosphene positioning system, 68–72
- Photodiodes, 12
- Planar electrodes, 27–28  
  technologies, 126*f*
- Plan–Do–Check–Act (PDCA) principle, 127, 127*f*, 142
- Plasma-enhanced chemical vapor deposition (PECVD), 24, 50–51
- Platinum gray, 32–34
- Platinum–iridium electrodes, 105
- Platinum(Pt) electrodes, 32
- PMA process, 361–364  
  application content, 362  
  “major deficiency letter” by FDA, 363  
  review process, 363*f*
- Polyurethane, 21, 226, 227, 232, 239, 240–241
- Post-stroke shoulder subluxation  
  RFB1 applications, 262–263  
  RFB2 applications, 265  
  transcutaneous electrical muscle stimulation, 263
- Praxis system, 253, 254  
  *See also* FES
- Premarket approval (PMA), 355
- Pressure ulcers (PUs), 264–265  
  BIONs, prevention of, 264–265
- Processing and control unit, neural stimulator, 53–54
- Programmable gain control (PGC), 95
- Prosthetic control unit (PCU), 283, 288, 289, 289*f*  
  operational functions of, 289–290
- Prosthetic master control unit (PMCU), 289–290
- Proton electronation reaction, 205
- Pt/Ir alloy shafts, 49–50
- Pudendal nerve stimulation, 267*f*
- R**
- Ranck, J. B., 164
- Real-time programming strategies, 179–180
- Rebscher, Stephen, 85–109
- Receiver and decoder  
  ASIC chip, 94–96  
  block diagram, 95*f*  
  internal unit, cochlear implants, 94–96  
  safety checks, 95
- Refractory headaches, treatment  
  BPB1 applications, 268–270
- Refractory ventricular tachycardia, 230
- Ren, Qiushi, 20, 43–81
- Retina, 3–5, 4*f*  
  IR irradiation, 25
- Retinal implants, 7, 25  
  candidate retina diseases for, 5–6  
  and stimulation, 7–8
- Retinitis pigmentosa (RP), 1, 5, 7
- RFB1, *see* First-generation RF-powered bion microstimulator (RFB1)
- RFB2, *see* Second-generation RF-powered bion microstimulator (RFB2)
- RFB1 applications  
  foot drop, 264  
  knee osteoarthritis, 263  
  post-stroke hand contractures, 263–264  
  pressure ulcer prevention, 264–265  
  shoulder subluxation in post-stroke patients, 262–263

- RFB2 applications
  - post-stroke hand and arm rehabilitation, 265–266
  - post-stroke shoulder subluxation, 265
- RF frame coding, 92
  - embedded mode, 92
  - expanded mode, 92–93, 92*f*
  - high rate, better performance, 94
- Rmet, 46–47
- Robotic devices, control of
  - artificial hand prosthesis, Warwick, 280*f*
  - flexion vs. deired hand position, 280*f*
  - positioning array in arm, implant surgery, 279*f*
  - “SNAVE”, prosthesis, 279
  - using human implants, 278–281
- S**
- Safety considerations, cochlear implants
  - biocompatibility, 104–105
  - energy exposure, 106–107
  - mechanical safety, 106
  - sterilization, 105–106
- Second-generation RF-powered bion
  - microstimulator (RFB2), 256–260, 257*f*
- Scala tympani, 97, 98, 99, 102
- Scene images, 67
- Schulman, Joseph, H., 253–271, 275–290
- Sealing rings, 225
- Second-generation battery-powered bion
  - microstimulator (BPB2), 261
- Sedation, 72
- Sensory anatomy in spinal cord, 156*f*
- Sensory neurons, 277
- Signal-to-noise ratio (SNR), 48
- Silicon-based microelectrode arrays, 50–52
- Silicon carbide (SiC) films, 24
- Silicone rubber, 240
  - encapsulation, 106
- Silicon microelectrode arrays, 46
- Single-channel cochlear implant system
  - commercialization by 3 M, 86
  - US FDA approval for, 86
- Single-and multiple-source systems, 170–172, 179
- Single-shank array, 144
- Slanted bed of nails (SBON) electrode, 278
- “SNAVE”, prosthesis, 279–280
- Soft case approach, 21–22
- Sonata device, 94
- SPEAK strategy vs. ACE strategy, 92
- Speech processor, 88–89
- Spinal cord stimulation (SCS), 155–159
  - clinical problems, 158
  - clinical programming time
    - device programming in operating room and post-implant, 177–178
    - device reprogramming, 178
    - historical programming approach, 176–177
    - real-time programming strategies, 179–180
  - computational models as an engineering tool, 167, 183–189
  - electrical stimulation of dCSF, 157–158
  - electric field optimization
    - contact size and spacing, 163–167
    - electrical management of lead migration, 173–176
    - electrical sources for stimulation, 167–173
    - number of implanted contacts, 162
  - ideal system, 160
  - in vitro design method, 160
  - monopolar impedance, variability, 162*f*
  - spinal cord stimulation therapy
    - clinical and physiological challenges, 161–162
    - paresthesia, 159–160
    - spinal cord stimulation, history, 155–159
    - stimulation parameters
      - pulse width, effects, 181–182
      - stimulation rate, effects, 182–183
- Split bipole configuration, 232
- Sputtered iridium oxide film (SIROF), 205
- Stanford and Biostem, joint agreement, 86
- Sterilization, 105–106
  - ethylene oxide (EtO), 105–106
  - implant components, design and structure, 106
  - safety factor, 105–106
- Stimulation microelectrode arrays, 34–36
- Stimulation safety and tissue response, 207–209
  - charge density limit for safe microstimulation, 207–208
- Stimulator
  - digital to analog converter (DAC), 96
  - internal unit, cochlear implants, 96
  - sources
    - cascode current mirrors, 96
    - trimmer network method, 96
- Stimulator, data packet format for, 53*f*

- Stimulator on tissues and heat damage,  
thermal effects of, 24–26
- Stokes Adams disease, 221
- Stokes, Ken, 221–248
- Striate cortex, 2
- Stylet, 127, 229
- Subclavian stick kit and procedure, 229*f*
- Suboccipital craniotomy, 136
- Subretinal implant, 12–15
- Substantially equivalent device, 355, 361
- Subthalamic nucleus (STN), 197  
primary topographic subdivisions of,  
schematic diagram, 198*f*  
treatment of behavioral disorders, target  
site, 197
- Sui, Xiaohong, 43–81
- Short-lasting, unilateral, neuralgiform  
headache attacks with  
conjunctival injection and tearing  
(SUNCT), 270
- Superior rectus muscle, 72
- SUNCT, *see* Short-lasting, unilateral,  
neuralgiform headache attacks  
with conjunctival injection and  
tearing (SUNCT)
- Sun, Xiaohan, 85–109
- Sun, Xiaodong, 43–81
- Surgical implantation, 16–17
- Sweet spot, 163
- Symbion device, 87
- SYNC burst, 92*f*, 93
- Synchronous dynamic random access  
memory (SDRAM), 57, 58
- T**
- Tachycardia, 221, 230, 231, 243, 244, 245
- Tactile board, 71
- Tactile perception using simulated prosthetic  
vision, 69–71
- Tantalum oxide, 255
- Tchemodanov, Natalia, 293–344
- Thermal noise, 46–47, 48
- Thin-film  
chip-size package, 22  
coating, 24  
electrode arrays, 28–30  
microelectrodes, 31–32
- Thoracotomy, 227
- Threshold-binarization images, 65
- Time Domain Multiplexed Access  
(TDMA), 289
- Tinnitus, 140
- Titanium in pacemaker and ICD  
containers, 238
- Titanium nitride, 31–32
- TMS320DM642, 57
- Touch sensors, 275
- Tourette’s syndrome, 198
- Transcutaneous electrical muscle  
stimulation, 263
- Transmission cell (T cell), 156
- Transvenous lead dislodgment,  
prevention, 227
- Transverse tripolar system (TTS), 173
- Tremor neurons, 210
- Trochlear nerve, 138
- Tungsten shafts, 48–49
- U**
- Ulbert, 201
- Ultrananocrystalline diamond (UNCD)  
coatings, 24
- University of Michigan  
silicon chip technology, research on, 276
- University of Twente Computational Model  
field steering between contacts parallel  
leads, 186  
pulse width, effect, 187–189  
sensitivity analysis of transverse tripolar  
stimulation, 184–186  
*See also* Spinal cord stimulation
- Urgency frequency syndrome (UF), 268
- Urinary urge incontinence (UII), 266
- US regulatory approval process, 353–354  
classification panels, 354–357  
clinical phase, 357–358  
clinical trials, 358–359  
domestic applications, types  
of, 359–360  
humanitarian device exemptions (HDEs),  
364–367  
510(k) review process, 360–361  
PMA process, 361–364
- “Utah array”  
saw-dicing method for probe  
implantation, 203
- Utah bed, development of  
bed of nails (BON) electrode array,  
design of, 278  
comparison of BON and SBON,  
illustration, 278*f*  
Utah electrode array (UEA) and Utah  
slanted electrode array,  
comparison, 279*f*

**V**

- VAT pacemaker, 222
- Vector Vision Navigation System, 138
- Venotomy, 230
- Veraart, 20, 54, 172
- Vision prostheses, 44
- Visual evoked potentials (VEP), 81
- Visual guide, 69
- Visual implants, 6
- Visual information, 44
  - processing, 56
- Visual pathway, 2–3
- Visual perception error, 69
- Visual phosphenes, 44
- Visual processing unit (VPU)<sup>TM</sup>, 10
- Visual prostheses, 1–2
  - biomedical engineering approaches
    - eye and retina, 3–5
    - retinal implants, candidate retina diseases for, 5–6
    - for visual implants, 6
    - visual pathway, 2–3
  - engineering challenges in development of, 20–21
  - electrode materials, *see* Visual stimulation electrodes
  - implant packaging and
    - biocompatibility, 21–24
    - stimulation microelectrode arrays, *see* Microelectrode arrays
  - surgical attachment of stimulation microelectrode arrays, 34–36
  - thermal effects of stimulator on tissues and heat damage, 24–26
  - microelectronic visual implant technologies
    - epiretinal implant, 8–12
    - extraocular implant, 15–17
    - optic nerve stimulation, 20
    - retinal stimulation and implants, 7–8
    - subretinal implant, 12–15
    - visual stimulation in brain, *see* Brain, visual stimulation
- Visual stimulation electrodes
  - capacitive electrodes, 30–31
  - iridium oxide, 32
  - platinum gray, 32–34
  - titanium nitride, 31–32
- Vitreous humor, 3–5, 3*t*

- VLIW architecture, 57
- VLSI-based multi-channel cochlear implant system, 86
- $\beta$  voltaic effect, 237
- VVI pacemaker, 222
- VVIR pacemaker, 222, 225

**W**

- Warren and Nelson
  - basic design elements, pacemaker and ICD, 237–238
- Warwick, Kevin, 278–281
  - artificial hand prosthesis, 280*f*
  - wheel chair, demonstration of, 281*f*
- Water window, 30
- Western Ontario McMaster (WOMAC), 263
- Wheel chair
  - sequencing box, 281
- Whitehurst, Todd, K., 253–271
- Wireless communication, 288–289
  - SBONs and PCU, 289*f*
  - time domain multiplexed access (TDMA), 289
  - UHF channel, 289
    - radio signal propagation, 289
- Wireless power
  - thermal effects and efficiency, 288
- Wu, Kaijie, 43–81

**X**

- X-ray image of DBS macroelectrode implantation, 196*f*
- Xu, Xun, 43–81

**Y**

- Y-adapters, 232
- Yang, Zhi, 293–344
- Young's modulus, 204

**Z**

- Zeng, Fan-Gang, 85–109
- Zhou, David, D., 1–36
- Zoll's AC powered asynchronous pacemaker, 222, 223*f*
- Zona incerta, 198, 210